The international chronic myelomonocytic leukemia (CMML) treatment market is witnessing a period of significant growth. This development can be attributed to several factors, such as the increasing incidence of CMML, advancements in treatment, and growing awareness about the disease. The market is marked by a diverse portfolio of treatments availab